Tag
GLP-1 receptor agonists reduce mortality and cardiovascular events more effectively than SGLT2 inhibitors in serious mental illness (SMI), with early benefits and consistent effects across bipolar disorder, major depression, and schizophren
This review synthesizes evidence on tailored weight loss programs for adults with serious mental illness, highlighting recent advances, effectiveness, mechanistic insights, and future directions.
This review synthesizes evidence from a 2025 randomized clinical trial evaluating a tailored weight loss program, CoachToFit, for veterans with serious mental illness, highlighting its potential to improve weight outcomes via remote support
This RCT demonstrates that disposable e-cigarettes significantly reduce carcinogen levels short-term among smokers with serious mental illness, underscoring the need for behavioral support to sustain harm reduction.
